Vical to present vaccine development programs

WASHINGTON -- Vical Inc. announced Jan. 26 that the company would present an overview of its DNA vaccine and adjuvant technologies and an update on its clinical-stage vaccine development programs at the Phacilitate Vaccine Forum, which concludes Jan. 27 in Washington.

Alain P. Rolland, Vical's executive vice president of product development, is scheduled to speak at 12:55 p.m. Jan. 27.

Rolland's presentation, "Delivery systems and adjuvants for DNA-based vaccines: Development of prophylactic and therapeutic vaccines," highlights the interim Phase 2 clinical data for the company's TransVax therapeutic cytomegalovirus vaccine for transplant recipients, and the development of its Vaxfectin-adjuvanted H5N1 and H1N1 pandemic influenza DNA vaccines.

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources.